Single Dose Bioequivalence Study of Darifenacin Tablets 7.5 mg in Fed Healthy Volunteers.
Information source: Center for Clinical Pharmacology Research Bdbeq S.A.
Information obtained from ClinicalTrials.gov on February 07, 2013
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Bioequivalency
Intervention: Darifenacin (Drug); Darifenacin (Drug)
Phase: Phase 1
Status: Not yet recruiting
Sponsored by: Center for Clinical Pharmacology Research Bdbeq S.A.
Official(s) and/or principal investigator(s):
Francisco E. Estevez-Carrizo, MD, Study Director, Affiliation: Univerisity of Montevideo. Biomedical Science Center.Prudencio de Pena 2440, 11600 Montevideo. Uruguay
Susana Parrillo, M.D., Principal Investigator, Affiliation: Center for Clinical Pharmacology Research Bdbeq S.A., Br. Artigas 1632. c.p. 11600 Montevideo. Uruguay.
Federico Santoro, MD, Phone: +541143794300, Email: email@example.com
The proposed study was designed as a randomized two-sequence, two period crossover trial to
assess the bioequivalence, pharmacokinetic profiling and safety of a brand generic
formulation of darifenacin [Darisec(R) 7. 5 mg] vs. the innovator [Enablex(R)7. 5 mg]in
healthy volunteers in postprandial state.
Official title: Comparative Bioavailability of Darifenacin Extended Release Oral Formulation [Darisec(R)7.5 mg vs. Enablex(R)7.5 mg]: Single-dose, Postprandial State, Randomized, Two-sequence, Two-period, Crossover Study in Healthy Volunteers.
Study design: Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label
Extent of absorption
Rate of absorption
Time to peak concentration (tmax)
Elimination rate constant (Ke)
Elimination Half-life (t1/2e)
Systemic clearance (Cls)
Darifenacin is a muscarinic receptor antagonist drug used to treat overactive bladder. There
is a new formulation of darifenacin extended release developed by an argentinian
pharmaceutical company. A bioequivalence study will be performed to validate pharmaceutical
development before introducing the product in the market.
The purpose in this study is to evaluate the relative bioavailability, pharmacokinetic
profiling and safety of a brand generic formulation of darifenacin [Darisec(R) 7. 5 mg] vs.
the innovator [Enablex(R) 7. 5 mg]in 24 healthy uruguayan volunteers after a high fat
breakfast of 1000 calories (50% fat, 35% carbohydrates, and 15% proteins)to establish their
The bioequivalence will be evaluated using:
- The Area Under the Curve (AUC),
- The peak plasma concentration (Cmax).
The pharmacokinetic characteristics of the drug formulations will be described calculating:
- The time to peak concentration (Tmax)
- The elimination constant (Ke)
- The elimination half-life (t1/2e)
- The systemic clearance (Cls)
Safety will be evaluated recording:
- Reported adverse events
- Vital signs (blood pressure, heart rate, body temperature)
- Laboratory analysis (hemogram, hepatic enzymes, creatinine, sugar in blood, etc.)
- EKG and chest XRays
Bioequivalence will be claimed if the drugs comply with local and FDA regulatory
- Mean AUCt/AUCr and 90% confidence interval within 0. 80-1. 25
- Mean Cmaxt/Cmaxr and 90% confidence interval within 0. 80-1. 25
Pharmacokinetic profiling will be evaluated by describing the pharmacokinetic
characteristics of both drug in adequate two-way tables.
Safety will be evaluated comparing incidence of adverse events/adverse effects for both
Minimum age: 18 Years.
Maximum age: 50 Years.
- Healthy male or female subjects 18 to 50 years of age (inclusive).
- In good health, as determined by lack of clinically significant abnormalities at
screening as judged by the physician.
- Female subjects are required to use a medically accepted method of hormonal
contraception or abstinence throughout the entire study period and for one week after
the study is completed.
- Body mass index within the range of 18. 5 and 29. 9 kg/m2 and weight at least 45 kg.
- Known hypersensitivity or severe adverse event to darifenacin or similar drugs.
- Urinary, retention, narrow-angle glaucoma, myasthenia gravis, severe hepatic
impairment, severe ulcerative colitis, toxic megacolon.
- Symptomatic hiatus hernia, erosive or symptomatic gastroesophageal reflux
disease/heartburn (>2 days in a week), severe constipation, gastrointestinal
obstructive disorder, and gastric retention.
- Clinically significant cardiac abnormalities, fainting, low blood pressure upon
standing, irregular heartbeats.
- Acute or chronic bronchospastic disease(including asthma and Chronic Obstructive
- Clinically significant drug allergy or history of atopic allergy (asthma, urticaria,
- Smokers of more than 5 cigarettes a week.
- Regular use of any drug known to induce or inhibit hepatic drug metabolism
(particularly those that affect CYP2D6) within 30 days prior to each study drug
- Any surgical or medical condition which might significantly alter the absorption,
distribution, metabolism, or excretion of drugs which may jeopardize participation in
- Immunodeficiency diseases, including a positive HIV (Elisa or Western blot) test
- Positive Hepatitis B Surface antigen (HBsAg) or Hepatitis C results.
- Drug or alcohol abuse within the 6 months prior to dosing.
- Use of prescription drugs within 1 month prior to dosing, or over-the-counter
medication (vitamins, herbal supplements, dietary supplements)within 2 weeks prior to
dosing. Paracetamol and ibuprofen are acceptable.
- Participation in any clinical investigation within 12 weeks prior to dosing.
- Donation or loss of 400 ml or more of blood within 8 weeks prior to dosing.
- Significant illness within 2 weeks prior to dosing.
- Other protocol-defined inclusion/exclusion criteria may apply.
Locations and Contacts
Federico Santoro, MD, Phone: +541143794300, Email: firstname.lastname@example.org
Center for Clinical Pharmacology Research (CCPR) Bdbeq S.A. Hospital Italiano., Montevideo 11600, Uruguay; Not yet recruiting
Francisco E. Estevez-Carrizo, M.D., Phone: +59824876288, Email: email@example.com
Mónica Cedrés, Pharm. B., Phone: +59824876288, Email: firstname.lastname@example.org
Susana Parrillo, M.D., Principal Investigator
Skerjanec A. The clinical pharmacokinetics of darifenacin. Clin Pharmacokinet. 2006;45(4):325-50. Review.
Croom KF, Keating GM. Darifenacin: in the treatment of overactive bladder. Drugs Aging. 2004;21(13):885-92; discussion 893-4. Review.
Staskin DR. Overactive bladder in the elderly: a guide to pharmacological management. Drugs Aging. 2005;22(12):1013-28. Review.
Kerbusch T, Wählby U, Milligan PA, Karlsson MO. Population pharmacokinetic modelling of darifenacin and its hydroxylated metabolite using pooled data, incorporating saturable first-pass metabolism, CYP2D6 genotype and formulation-dependent bioavailability. Br J Clin Pharmacol. 2003 Dec;56(6):639-52.
Dmochowski RR, Appell RA. Advancements in pharmacologic management of the overactive bladder. Urology. 2000 Dec 4;56(6 Suppl 1):41-9. Review.
Starting date: December 2010
Last updated: October 26, 2010